Renal Cancer - Results from #2140

Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC) - an International mRCC Database Consortium (IMDC) analysis. March 8, 2021

A Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Versus Pembrolizumab Plus Axitinib and Versus Avelumab Plus Axitinib in First-Line Treatment of Advanced Renal Cell Carcinoma. March 8, 2021

Association between Immune Related Adverse Events and Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. March 8, 2021

Tumor Stage and Substage Predict Cancer-specific Mortality After Nephrectomy for Nonmetastatic Renal Cancer: Histological Subtype-specific Validation. March 5, 2021

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. March 5, 2021

Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes. March 4, 2021

Construction and validation of an autophagy-related long noncoding RNA signature for prognosis prediction in kidney renal clear cell carcinoma patients. March 4, 2021

Outcome of advanced renal cell carcinoma arising in end-stage renal disease: comparison with sporadic renal cell carcinoma. March 3, 2021

Enhanced Recovery after Robot-Assisted Partial Nephrectomy for Cancer: Is it Better for Patients to Have a Quick Discharge? March 3, 2021

Phase IB study of sorafenib and evofosfamide in patients with advanced hepatocellular and renal cell carcinomas (NCCTG N1135, Alliance). March 3, 2021

Claudin-2 inhibits renal clear cell carcinoma progression by inhibiting YAP-activation. March 2, 2021

Outcome after resection of occult and non-occult lymph node metastases at the time of nephrectomy. March 2, 2021

Clinical utility of FDG PET/CT for primary and recurrent papillary renal cell carcinoma. March 2, 2021

Percutaneous Ablation Versus Surgical Resection for Local Recurrence Following Partial Nephrectomy for Renal Cell Cancer: A Propensity Score Analysis (REPART Study-UroCCR 71). March 1, 2021

The prognostic value of fat invasion and tumor expansion in the hilar veins in pT3a renal cell carcinoma. March 1, 2021

Real-world symptoms, disease burden, resource use and quality of life in US patients with advanced renal cell cancer. March 1, 2021

Cracking the Case of a Deadly Type of Kidney Cancer February 26, 2021

Coffee consumption and risk of renal cell carcinoma in the NIH-AARP Diet and Health Study. February 26, 2021

Influence of treatment access on survival of metastatic renal cell carcinoma in brazilian cancer center. February 26, 2021

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. February 25, 2021

Page 108 of 456